Results 251 to 260 of about 555,062 (342)

Follow‐up of osteonecrosis in paediatric acute lymphoblastic leukaemia patients treated with the NOPHO ALL2008 protocol

British Journal of Haematology, EarlyView.
Summary Although osteonecrosis (ON) is a common sequel after childhood acute lymphoblastic leukaemia treatment and may cause debilitating symptoms, its prognosis remains underexplored. We describe the radiological evolution of ON lesions in a Finnish patient cohort treated according to the The Nordic Society of Paediatric Haematology and Oncology ...
Roosa Rokkanen, Henri Aarnivala, Sanna Huhtaniska, Sauli Palmu, Tytti Pokka, Tuuli Pöyhönen, Maria Suo‐Palosaari, Pauliina Utriainen, Liisa Järvelä, Riitta Niinimäki   +9 more
wiley   +1 more source

Overweight or Obesity and Outcomes in Children With Acute Lymphoblastic Leukemia.

JAMA Netw Open
Ladas EJ, Sheng H, Athale UH, Asselin BL, Clavell LA, Cole PD, Flamand Y, Leclerc JM, Laverdiere C, Michon B, Sallan SE, Silverman LB, Welch JJG, Yao S, Kelly KM.   +14 more
europepmc   +1 more source

Mutational signatures and kataegis in pediatric B-cell precursor acute lymphoblastic leukemia. [PDF]

Hemasphere
Gunnarsson R, Yang M, Biloglav A, Lundin-Ström KB, Lilljebjörn H, Castor A, Fioretos T, Olsson-Arvidsson L, Paulsson K, Johansson B.   +9 more
europepmc   +1 more source

Targeting SHP‐1‐Mediated Inhibition of STAT3 and ERK Signalling Pathways Rescues the Hyporesponsiveness of MHC‐I‐Deficient NK‐92MI

Cell Proliferation, EarlyView.
B2M knockout (KO) represents a crucial strategy for generating universal NK‐92MI cell products. This approach results in increased phosphorylation of SHP‐1 and inhibited phosphorylation of STAT3 and ERK, which ultimately affect their cytotoxic capabilities. SHP‐1 KO facilitates the restoration of cytotoxic function in B2M KO NK‐92MI cells.
Kuo Yu, Xiaolong Liu, Guangyuan Wu, Zhongyao An, Xin Wang, Yang Liu, Hailong Wang, Mingli Huang, Linlin Zhao, Ce Shi, Xin Sun, Lu Xu, Sen Qi, Xin Zhang, Yueqiu Teng, Song Guo Zheng, Zhiren Zhang, Zhenkun Wang   +17 more
wiley   +1 more source

Ex vivo drug responses and molecular profiles of 597 pediatric acute lymphoblastic leukemia patients. [PDF]

Hemasphere
Enblad AP, Krali O, Gezelius H, Lundmark A, Blom K, Andersson C, Palle J, Frost BM, Ryhänen S, Flægstad T, Jónsson ÓG, Schmiegelow K, Heyman M, Harila A, Nygren P, Larsson R, Lönnerholm G, Nordlund J.   +17 more
europepmc   +1 more source

RBM39 Promotes Base Excision Repair to Facilitate the Progression of HCC by Stabilising OGG1 mRNA

Cell Proliferation, EarlyView.
Targeting RBM39 attenuates BER via destabilising OGG1 mRNA and potentiates KBrO3‐induced oxidative stress in HCC. Our study represents a valuable treatment strategy combining indisulam and an oxidative stress inducer in HCC. ABSTRACT Targeting base excision repair (BER) has been an attractive strategy in cancer therapeutics.
Hongda An, Anliang Xia, Siyuan Liu, Dongjun Luo, Longpo Geng, Binghua Li, Beicheng Sun, Zhu Xu   +7 more
wiley   +1 more source

Does allopurinol enhance efficacy of acute lymphoblastic leukemia maintenance therapy? [PDF]

Haematologica
Schmiegelow K, Toksvang LN, Conter V.
europepmc   +1 more source

Hematopoietic stem cell transplantation for adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first remission: a position statement of the European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL) and the Acute Leukemia Working Party of the European Society for

Bone Marrow Transplantation, 2018
S. Giebel, D. Marks, N. Boissel, F. Baron, S. Chiaretti, F. Ciceri, J. Cornelissen, M. Doubek, J. Esteve, A. Fielding, R. Foà, N. Gorin, N. Gökbuget, H. Hallböök, D. Hoelzer, Elena Paravichnikova, J. Ribera, B. Savani, Anita W Rijneveld, C. Schmid, U. Wartiovaara-Kautto, M. Mohty, A. Nagler, H. Dombret   +23 more
semanticscholar   +1 more source

PI5P4K inhibitors: promising opportunities and challenges

The FEBS Journal, EarlyView.
Developing inhibitors is like climbing a steep, challenging mountain. PI5P4K inhibitors hold significant promise for the treatment of cancer, immune disorders, and neurological diseases. However, the path to success is fraught with hurdles, and researchers are therefore required to apply their expertise to overcome critical “checkpoints.” While some ...
Koh Takeuchi, Lisa Nagase, Shun Kageyama, Hirotaka Kanoh, Masashi Oshima, Aki Ogawa‐Iio, Yoshiki Ikeda, Yuki Fujii, Sei Kondo, Natsuki Osaka, Takeshi Masuda, Tsukasa Ishihara, Yoshikazu Nakamura, Yoshihisa Hirota, Takehiko Sasaki, Toshiya Senda, Atsuo T. Sasaki   +16 more
wiley   +1 more source

Moving cellular therapies to the front line for Ph⁺ B cell acute lymphoblastic leukemia. [PDF]

Cell Rep Med
Feng Y, Leveille E, Park JH, Müschen M.
europepmc   +1 more source